ArticleProceedings (Baylor University. Medical Center)2026
Demographics and factors influencing mortality among cardiac angiosarcoma patients and genomic studies correlation for future personalized management.
Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac angiosarcoma is a rare, highly aggressive malignancy arising from endothelial cells of the heart and accounts for ∼30% of primary cardiac tumors. Understanding its epidemiology and factors influencing mortality is critical, and emerging genomic data may inform personalized management.
methodsThe Surveillance, Epidemiology, and End Results database was utilized to gather data from 2000 to 2021.
resultsA total of 194 patients were identified (102 males and 92 females). Most patients were ≤50 years (59%), with a slightly higher incidence among Black patients (18%). Overall mortality was high, with 91% of patients dying and a mean survival of 15 months. The 1-year overall survival rate was 0.461 (95% CI: 0.39-0.53). Larger tumors (>10 cm) and higher tumor grade were associated with increased mortality. Multivariate analysis showed that age 51-70 years (hazard ratio [HR] 0.57;
conclusionsCardiac angiosarcoma carries a high mortality rate. Advanced age, distant disease, and lack of surgery or radiation therapy were associated with increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.